NAN-101 in Patients With Class III Heart Failure (NAN-CS101)

• ClinicalTrials.gov Identifier: NCT04179643
• Recruitment Status: Recruiting
• First Posted: November 27, 2019
• Last Update Posted: December 3, 2019
• Sponsor: Asklepios Biopharmaceutical, Inc.
• Information provided by (Responsible Party): Asklepios Biopharmaceutical, Inc.

Study Description

Brief Summary:

This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of BNP116.sc-CMV.I1c in patients with NYHA Class III heart failure. Patients with symptomatic congestive heart failure will be enrolled until up to 12 subjects have received infusions of investigational product. All patients will be followed until 12 months post treatment intervention, and then undergo long-term follow-up via semi-structured telephone questionnaires every 6 months for an additional 24 months (+/- 30 days).

Condition or disease	Intervention/treatment	Phase
Congestive Heart Failure; Heart Failure; Heart Disease, Ischemic; Cardiovascular Diseases; Heart Failure, Systolic; Heart Failure，Congestive; Heart Arrhythmia; Heart Failure, Diastolic; Heart; Complications	Biological: 3 x 10e13vg NAN-101	Phase 1

Detailed Description:

The primary endpoint for this study is safety as measured by the following which will be assessed over the 12 month follow-up period as indicated in the Data Collection Table:

• Adverse Events
• All-cause Mortality
• Heart failure (HF) Hospitalization

Secondary Endpoints

The secondary safety endpoints assessed will include the following:

• Echocardiographic assessments at 4 weeks +/- 3 days post-administration of BNP116.sc-CMV.I1c including
• Echocardiographic assessments of LVEF, LVEVD, LVEDVI, VLESV, LVEVI, SpI and GLSand degree of mitral regurgitation o

The secondary efficacy endpoints will explore efficacy. Functional endpoints will be assessed as changes from baseline to 6 and 12 months following investigational product administration as indicated. These endpoints include:

Functional Status & Hospitalizations

• Peak VO2 assessed by cardiopulmonary exercise testing
• 6-minute walk test
• New York Heart Association (NYHA) Classification
• Total number of days alive out-of-hospital (as well as total days out-of-hospital as a % of total days alive post study intervention)

Physiologic Assessments at 6 and 12 months compared to baseline

• Echocardiographic assessments of LVEF, LVEVD, LVEDVI, VLESV, LVEVI, SpI and GLSand degree of mitral regurgitation
• NT-proBNP level

Quality of Life at 6 and 12 months compared to baseline

o Health related quality of life as assessed by Minnesota Living with Heart Failure Questionnaire (MLWHFQ)

The following endpoints will also be measured over the 12 month follow-up period and long-term follow-up period (until month 36 post-intervention):

• Survival
• Cardiac transplantation
• Left ventricular assist device (LVAD) implantation

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 12 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart Failure
• Actual Study Start Date: November 20, 2019
• Estimated Primary Completion Date: December 31, 2020
• Estimated Study Completion Date: July 31, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: 3 x 10e13vg NAN-101; Intracoronary Infusion of NAN-101 at 3 x 10e13vg up to 4 subjects	Biological: 3 x 10e13vg NAN-101; There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
Experimental: 1 x 10e14vg NAN-101; Intracoronary Infusion of NAN-101 1 x 10e14vg up to 4 subjects	Biological: 3 x 10e13vg NAN-101; There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
Experimental: 3 x 10e14 vg NAN-101; Intracoronary Infusion of NAN-101 3 x 10e14 vg up to 4 subjects	Biological: 3 x 10e13vg NAN-101; There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.

Outcome Measures

Primary Outcome Measures :

1. Observed and change from baseline in Peak VO2 [ Time Frame: Measured at screening, month 6 and month 12 ]
   Cardiopulmonary exercise testing using a modified Bruce protocol
2. Observed and change from baseline in Echocardiographic assessment in Left Ventricular Ejection Fraction [ Time Frame: Measured at screening, 18-24 hours post intervention, week 4, Month 6 and Month 12 ]
   Echocardiography LVEF measurement

Secondary Outcome Measures :

1. Observed and change from baseline in 6-minute walk test distance [ Time Frame: Measured at screening, Month 6 and month 12 ]
   Analysis of Percent predicted in heart failure subjects compared to normal subjects

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

• Age >18 years of age
• Chronic non-ischemic cardiomyopathy
• LVEF ≤ 30% by transthoracic echocardiography (TTE) within 6 months prior to enrollment

• NYHA Class III HF for a minimum of 6 months HF despite appropriate medical therapy (defined below):

  • Treatment with appropriate HF therapy as tolerated, including, but not limited to:
  • Beta blocker therapy and angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) or sacubitril/valsartan combination therapy (Entresto) for ≥ 90 days prior to enrollment. May also receive aldosterone antagonist therapy. Doses of the above medications must be stable for ≥ 30 days prior to enrollment; and
  • Cardiac resynchronization therapy (CRT), if clinically indicated, must have been implanted ≥ 90 days prior to enrollment. Internal cardioverter defibrillator (ICD) must be implanted, if clinically indicated ≥ 30 days prior to enrollment
• Females of childbearing potential must use at least one of the following acceptable birth control methods throughout the study and for 6 months after IP administration:
• Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum prior to IP administration
• Intrauterine device in place for at least 90 days prior to receiving IP
• Barrier methods (diaphragm plus spermicide or condom) starting at least 30 days prior to receiving IP
• Abstinence (the subject must be willing to remain abstinent from screening to 6 months after receiving IP). Females are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject
• Surgical sterilization of the partner(s) (vasectomy) for >180 days prior to IP administration
• Hormonal contraceptives starting > 90 days prior to IP. If hormonal contraceptives are started less than 90 days prior to receiving IP, subjects must agree to use a barrier method (diaphragm plus spermicide or condom) from screening through 90 days after initiation of hormonal contraceptives
• Males subjects capable of fathering a child:
• Must agree to use a condom from IP administration through 6 months after the time of IP administration
• Must agree not to donate sperm for 6 months after time of receiving IP
• Documented evidence of vasectomy in males for 180 days minimum prior to receiving IP is an acceptable form of contraception
• Males who claim abstinence as their method of contraception are allowed provided they agree to use barrier methods should they become sexually active from screening through 6 months after receiving IP. Males are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject
• Ability to sign Informed Consent Form (ICF) and Release of Medical Information Form
• Appropriate candidate for protocol-specified intracoronary infusion in the judgment of the infusing interventional cardiologist

Exclusion Criteria:

• Chronic ischemic cardiomyopathy
• Intravenous (IV) inotropic therapy, intra-aortic balloon pump (IABP) or percutaneous cardiac assist device therapy within 30 days prior to enrollment
• Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic LV aneurysm
• Cardiac surgery or percutaneous coronary intervention (PCI) within 30 days prior to enrollment
• Third degree heart block
• Clinically significant myocardial infarction (MI) in the judgment of the subject's physician (e.g., ST elevation MI [STEMI] or large non-STEMI) within 6 months prior to enrollment
• Prior heart transplantation, left ventricular reduction surgery (LVRS), cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device), surgically implanted LVAD or cardiac shunt
• Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LV reduction surgery, heart transplant, conventional revascularization procedure, or valvular repair within 3 months of IP dosing
• Known hypersensitivity to contrast dyes used for angiography; history of, or likely need for, high-dose steroid pretreatment prior to contrast angiography
• Expected survival < 1 year in the judgment of the investigator
• Active or suspected infection within 48 hours prior to enrollment as evidenced by fever or positive culture
• Known intrinsic liver disease (e.g., cirrhosis, hepatitis A, chronic hepatitis B or hepatitis C virus infection). If serology is positive and PCR is negative, subject may be eligible (confirm with medical monitor).
• Liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase) > 2x upper limit of normal (ULN) within 30 days prior to enrollment.
• Renal Failure, dialysis dependent or serum creatinine > 2.5 mg/dl within 30 days prior to enrollment
• Bleeding diathesis or thrombocytopenia defined as platelets <50,000 platelets/μL within 30 days prior to enrollment
• Anemia defined as hemoglobin <10 g/dL or transfusion dependent within 30 days prior to enrollment
• Neutropenia defined as absolute neutrophils <1500 mm3 within 30 days prior to enrollment
• Known AIDS or HIV-positive status, or a previous diagnosis of immunodeficiency with an absolute neutrophil count <1000 cells/mm3
• Previous participation in a study of gene transfer
• Receiving investigational intervention or participating in another clinical study within 30 days or within 5 half-lives of another investigational drug administration prior to administration of NAN-101 that may impact the therapeutic potential of NAN-101.
• Pregnancy or breastfeeding at the time of screening

Contacts and Locations

Locations

United States, Minnesota

Minneapolis Heart Foundation Institute; Not yet recruiting

Minneapolis, Minnesota, United States, 55407

Contact: Jake Jensen 612-863-3818 jacob.jensen@allina.com

Principal Investigator: Jay Traverse, MD

United States, Ohio

The Linder Center for Education and Research at The Christ Hospital; Recruiting

Cincinnati, Ohio, United States, 45219

Contact: Meredith Kaczmarek, RN 513-585-1790 Meredith.Kaczmarek@thechristhospital.com

Principal Investigator: Timothy D Henry, MD

The Ohio State University; Not yet recruiting

Columbus, Ohio, United States, 43210

Contact: Shawna Oxier, RN 614-247-6797 shawna.oxier@osumc.edu

Principal Investigator: Konstantinos Boudoulas, MD

United States, Wisconsin

University of Wisconsin at Madison; Not yet recruiting

Madison, Wisconsin, United States, 53792

Contact: Soni VanderArk, MD 608-265-0612 cav@medicine.wisc.edu

Principal Investigator: David Murray, MD

Sponsors and Collaborators

Asklepios Biopharmaceutical, Inc.

More Information

• Responsible Party: Asklepios Biopharmaceutical, Inc.
• ClinicalTrials.gov Identifier: NCT04179643
• Other Study ID Numbers: NAN-CS101
• First Posted: November 27, 2019
• Last Update Posted: December 3, 2019
• Last Verified: November 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Heart Failure; Heart Diseases; Heart Failure, Systolic; Heart Failure, Diastolic; Myocardial Ischemia; Cardiovascular Diseases; Vascular Diseases